^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Astrocytoma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    PLX4720 (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

    Excerpt:
    To determine possible additive antitumor activity, a treatment group was included to evaluate PLX4720 + PD0332991 combination therapy. Bioluminescence monitoring of this treatment group showed further reduction of intracranial tumor growth rate, relative to either monotherapy (Fig. 4B), as well as increased survival benefit (Fig. 4C).
    DOI:
    10.1073/pnas.1117255109